^
BIOMARKER:

Chr amplification(11)(q23)

News
Twitter
Trials
Chr amplification(11)(q23)
CLL
venetoclax
Resistant: C3 – Early Trials
Chr amplification(11)(q23)
HCC
Immunotherapy
Sensitive: C3 – Early Trials